Highlights

  • IperionX (ASX:IPX) is developing a US-based titanium Supply chain supported by defence Demand and critical-minerals initiatives.
  • The company is targeting approximately 200 tonnes per annum production capacity at its Virginia Facility by the end of 2026.
  • IperionX secured approximately US$50 million through a July 2026 Equity raising to support expansion and project development.
  • Investors are focused on commercial production milestones, government funding, customer agreements and execution risk.

IperionX (ASX:IPX) has attracted renewed investor attention as demand for critical minerals and domestic supply chains supports interest in alternative titanium producers. The company is positioned around a strategy to develop lower-emission titanium production capabilities in the United States, supported by government funding and defence-related demand. However, the Business remains in a development phase, meaning the next stage depends heavily on successful production scaling and commercial customer conversion.

A critical-minerals theme meets a commercial challenge

IperionX has become a closely watched name among investors seeking exposure to the reshoring of critical-minerals supply chains.

The company is developing titanium production technology designed to provide an alternative to traditional titanium Manufacturing methods.

The Investment case is linked to several major themes:

  • US efforts to strengthen domestic defence supply chains;
  • demand for aerospace-grade titanium;
  • reduced reliance on overseas mineral processing;
  • broader critical-minerals investment.

However, IperionX remains a pre-commercial company.

The key challenge is moving from successful technology development and prototype activity into consistent commercial production.

The Key Development

A major milestone for IperionX was the completion of its Definitive Feasibility Study for the Titan critical-minerals project.

Released in June 2026, the study outlined the potential scale of the project, including:

  • after-tax NPV8 of US$813 million;
  • internal rate of return of 39.4%;
  • payback period of approximately 3.6 years;
  • around US$1.9 billion of projected free Cash Flow over the 14-year plan.

The Titan project is designed to produce titanium, zircon and rare-earth minerals within the United States.

The company has also expanded its mineral asset base through additional acquisitions, including Atlas mineral property additions adjacent to Titan.

Another strategic development was the proposed redomiciliation through a new Texas-based Parent Company structure, with the intention of establishing a Nasdaq-primary listing structure, subject to approvals.

Financial Performance

IperionX remains a development-stage company, meaning Earnings are not the primary measure of progress.

At 30 June 2026, the company held approximately US$35.2 million in cash.

Following its July Capital raising and expected government reimbursements, pro-forma cash increased to approximately US$84 million.

The July 2026 equity raising was a significant funding event.

IperionX completed an underwritten offering of 2,275,000 American Depositary Shares at US$21.98 per share, raising approximately US$50 million in gross proceeds.

The funds are being directed toward expanding the Virginia operation and progressing the Titan project.

Government funding remains an important component of the company's capital structure.

IperionX has secured:

  • up to US$47.1 million through an Industrial Base Analysis and Sustainment award;
  • a US$12.7 million Defense Production Act Title III award;
  • access to an SBIR Phase III pathway with potential funding of up to US$99 million.

This support reduces some funding pressure but also means the company remains dependent on government milestones and continued external capital.

What Management Is Saying

Management's focus is on moving from technology validation toward commercial-scale production.

The company is targeting approximately 200 tonnes per annum production capacity at its South Boston, Virginia facility by the end of 2026.

During the June quarter, the facility moved to 24/7 operations and commissioned an advanced 300-tonne SACMI press.

IperionX has stated that its HAMR titanium powder consistently meets or exceeds Grade 5 titanium specifications.

Management has also highlighted customer validation as an important step toward commercialisation.

The company has worked with defence and industrial customers, including prototype applications involving titanium fasteners.

Directors and executives have also participated in company share purchases, signalling confidence in the long-term strategy.

Why Investors Are Reacting

Investor interest in IperionX is being driven by both company-specific progress and broader sector sentiment.

The positive case centres on the company's position within US critical-minerals policy.

A domestic titanium supply chain has strategic importance for defence, aerospace and advanced manufacturing industries.

The company has also demonstrated technical progress through prototype production and customer testing.

However, the market remains divided because the commercial proof point has not yet been fully achieved.

The July equity raising highlighted this tension.

While the capital strengthens the Balance Sheet and supports expansion, dilution concerns affected investor sentiment.

The stock's Volatility also reflects significant short interest and the broader sensitivity of critical-minerals companies to changes in market appetite.

What Could Drive the Stock Next

The most important milestone is achieving the targeted Virginia production scale.

Reaching the 200 tonnes per annum target would provide stronger evidence that IperionX can move from development into repeatable manufacturing.

Other potential catalysts include:

  • new defence, aerospace or automotive supply agreements;
  • additional government funding releases;
  • progress toward Titan project financing;
  • commercial-scale customer contracts;
  • approval of the proposed redomiciliation structure.

The ability to convert prototype relationships into Recurring Revenue agreements will be central to the long-term investment case.

Risks to Watch

The largest risk remains commercial execution.

IperionX is still pre-revenue and depends on successfully scaling a developing production process.

Moving from prototypes to large-scale manufacturing introduces technical, operational and timing risks.

Further capital requirements are another consideration.

Although government support reduces funding pressure, additional equity raises may be required before the business becomes self-sustaining.

Customer adoption is also critical.

Prototype validation does not guarantee long-term commercial contracts, particularly in industries with strict qualification requirements.

Sector sentiment remains another risk.

A decline in critical-minerals enthusiasm or changes in government funding priorities could affect valuation.

Titanium pricing, defence procurement cycles and broader industrial demand also remain important external factors.

Investor Takeaway

IperionX (ASX:IPX) offers exposure to a major strategic theme: building alternative US-based titanium supply chains.

The company has attracted government support, advanced its Virginia production facility and outlined attractive Economics for the Titan project.

However, the investment case remains dependent on execution.

The next stage is not about proving the opportunity exists, but proving that the technology can scale into a commercially viable production business.

Investors should focus on production milestones, customer agreements, funding progress and the pace at which the company converts its strategic opportunity into sustainable revenue.